F087 Sarcopenia risk in Huntington’s disease

<h3>Background</h3> Sarcopenia is defined by low levels of muscle strength, muscle quantity/quality, and, physical performance (1). Although sarcopenia in clinical cases is observed in Huntington’s disease (HD) the clinical diagnosis is still challenging. The Consensus 20191 recommends 2 tools for early identification of cases at risk: Strength, assistance walking, rise from a chair, climb stairs, and fall questionnaire (SARC-F) (2) and the Ishii Test (3). <h3>Aims</h3> To assess the concordance between SARC-F and SARC-CalF (4) vs. Ishii test in HD. <h3>Methods/Techniques</h3> Cross-sectional and observational study. SARC-F is a 5-item questionnaire that is self-reported by patients based on the self-perception. SARC-CalF uses the same scores as SARC-F plus calf circumference measurement. On the other hand, Ishii test included age, grip strength, and calf circumference, assessed by health personnel. To analyze concordance, we used the Cohen´s kappa coefficient (CK Coef.). <h3>Results/Outcome</h3> Thirty-seven self-ambulatory participants, 60% women, CAG 43 ± 2.76, age 53.4 ± 11.9 years, BMI 24.3 ± 2.9, 62% moderate-high adherence Mediterranean diet, UHDRS motor 29.8 ± 22.1 and TFC 9.6 ± 3.2. The CK coef. were SARC-F vs. Ishii test 0.36 (p&lt;0.05), and SARC-CalF vs. Ishii test 0.55 (p&lt;0.05). <h3>Conclusions</h3> In HD, compared to the Ichii test, SARC-F cannot identify early cases at risk for sarcopenia. However, SARC-CalF had higher concordance with the Ichii test compared to SARC-F. The identification of cases at risk of sarcopenia is important and needs early lifestyle interventions, including physical activity and Mediterranean diet. Further research is needed to confirm these findings and the benefits of early lifestyle interventions. <h3>References</h3> Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;<b>48</b>(1):16-31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019 Jul 1;48(4):601. PMID: 30312372; PMCID: PMC6322506. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016 Mar;<b>7</b>(1):28-36. doi: 10.1002/jcsm.12048. Epub 2015 Jul 7. PMID: 27066316; PMCID: PMC4799853. Ishii S, Tanaka T, Shibasaki K, Ouchi Y, Kikutani T, Higashiguchi T, Obuchi SP, Ishikawa-Takata K, Hirano H, Kawai H, Tsuji T, Iijima K. Development of a simple screening test for sarcopenia in older adults. Geriatr Gerontol Int. 2014 Feb;<b>14</b> Suppl 1:93-101. doi: 10.1111/ggi.12197. PMID: 24450566. ( Barbosa-Silva TG, Menezes AM, Bielemann RM, Malmstrom TK, Gonzalez MC; Grupo de Estudos em Composição Corporal e Nutrição (COCONUT). Enhancing SARC-F: Improving Sarcopenia Screening in the Clinical Practice. J Am Med Dir Assoc. 2016 Dec 1;17(12):1136-1141. doi: 10.1016/j.jamda.2016.08.004. Epub 2016 Sep 17. PMID: 27650212.